View Financial HealthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsDancann Pharma 배당 및 자사주 매입배당 기준 점검 0/6Dancann Pharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-172.7%자사주 매입 수익률총 주주 수익률-172.7%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.공시 • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025공시 • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025공시 • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.공시 • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025공시 • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.공시 • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.공시 • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024공시 • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.공시 • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024공시 • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.공시 • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024공시 • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.공시 • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 DCPX.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: DCPX.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Dancann Pharma 배당 수익률 vs 시장DCPX.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (DCPX.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (DCPX.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 DCPX.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 DCPX.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 DCPX.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: DCPX.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2024/04/02 22:19종가2024/01/04 00:00수익2023/12/31연간 수익2023/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스DanCann Pharma A/S는 3명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Markus AugustssonCarlsquare ABJonatan AnderssonCarlsquare ABFredrik NilssonCarlsquare AB
공시 • May 21Dancann Pharma A/S Receives Regulatory Approval for Bedrolite and Bedrobinol from the Danish Medicines Agency Under the Danish Pilot ProgrammeDanCann Pharma A/S announced that the Company has obtained approval from the Danish Medicines Agency for the distribution of Bedrolite®? and Bedrobinol®? under the Danish Medicines Agency. The approval of these new products is in line with the Company's communicated guidance and is expected to have a positive impact on sales performance going forward. DanCann Pharma has received confirmation of regulatory approval for the distribution of two additional products in the Danish medicinal cannabis market from the Danish Medicines Agency. This regulatory milestone further strengthens DanCann Pharma's strategic positioning and leadership within Denmark's tightly regulated framework for medicinal cannabis and underscores the Company's ongoing commitment to broadening patient access to standardized, high-quality cannabinoid-based therapies. Bedrolite®? and bedrobinol®? Bedrolite®? represents the first Cannabidiol ("CBD")-dominant granulate product to be approved under the Pilot Programme in Denmark. The product contains approximately 9% CBD and less than 1% delta-9-tetrahydrocannabinol ("THC"). Inhalation as a delivery method allows for rapid onset of action, typically within 5-10 minutes, which is advantage for managing acute symptoms. The method also enables precise self-titration by patients and avoids first-pass hepatic metabolism, thereby improving bioavailability compared to oral formulations (e.g. oils, extracts and tinctures). Under the current framework of the Danish Pilot Programme for medicinal cannabis, the products are prescribable by all licensed medical practitioners and are eligible for public reimbursement in accordance with the reimbursement scheme established under the Pilot Programme for medicinal cannabis. Under the Danish pilot Programme for medicinal cannabis, patients are eligible for government reimbursement covering 50% of their annual treatment costs, up to a maximum of DKK 20,000 per year. The expected retail price for the newly approved products (Bedrolite®? and Bedrombinol®? in 5-gram units) is approximately DKK 500.00, inclusive of VAT and pharmacy fees. After reimbursement, the effective out-of-pocket cost to the patient is approximately DKK 250.00 per unit--equivalent to around DKK 50.00 per gram. This cost may be further reduced for patients who are members of the private health insurance scheme "Danmark", depending on their membership group and applicable coverage terms.
공시 • Apr 24+ 1 more updateDanCann Pharma A/S to Report Q3, 2025 Results on Oct 27, 2025DanCann Pharma A/S announced that they will report Q3, 2025 results at 6:00 PM, Central European Standard Time on Oct 27, 2025
공시 • Apr 11DanCann Pharma A/S to Report Q1, 2025 Results on Apr 28, 2025DanCann Pharma A/S announced that they will report Q1, 2025 results on Apr 28, 2025
공시 • Apr 05DanCann Pharma A/S Provides Financial Guidance for 2025DanCann Pharma A/S provided Financial guidance for 2025. For the period, the company expects revenue in the range of DKK 10.0 million to DKK 12.5 million.
공시 • Mar 28DanCann Pharma A/S to Report Fiscal Year 2024 Results on Apr 04, 2025DanCann Pharma A/S announced that they will report fiscal year 2024 results on Apr 04, 2025
공시 • Feb 17DanCann Pharma A/S Provides Earnings Guidance for the Year 2025 and 2026DanCann Pharma A/S provided earnings guidance for the year 2025 and 2026. In 2025, The company anticipates reaching between DKK 10.0 million and DKK 12.5 million, representing a YoY increase of 29.9% to 62.3% compared to the realized revenue (NET) of DKK 7.7 Million in 2024. Looking further ahead, its 2026 revenue guidance is set at DKK 20.0 million to DKK 25.0 million, a doubling (+100% YoY) of 2025 revenue, underlining the scalability of its business model and the anticipated impact of strategic initiatives.
공시 • Dec 11DanCann Pharma A/S Elects Jes Lunde as Additional Member of the Board of DirectorsDanCann Pharma A/S at its extraordinary general meeting was held on 10 December 2024, approved Jes Lunde shall be elected as the additional member of the board of directors.
공시 • Oct 31DanCann Pharma A/S to Report Q3, 2024 Results on Nov 29, 2024DanCann Pharma A/S announced that they will report Q3, 2024 results on Nov 29, 2024
공시 • Aug 14DanCann Pharma A/S Revises Earnings Guidance for 2024DanCann Pharma A/S revised earnings guidance for 2024. For the period, the company now expects revenue in the range of DKK 11.0 million to DKK 12.0 million, adjusted from the previous DKK 13.3 million. The guidance has been adjusted due to delays in the processes of the Danish Medicines Agency, which have also affected the Company's ongoing product approvals. As a result, the Company has slightly revised down its revenue expectations for 2024.
공시 • Aug 01DanCann Pharma A/S to Report Q2, 2024 Results on Aug 30, 2024DanCann Pharma A/S announced that they will report Q2, 2024 results on Aug 30, 2024
공시 • Jun 20DanCann Pharma A/S Provides Revenue Guidance for the Year 2024DanCann Pharma A/S provided revenue guidance for the year 2024. For the year, the company expected to generate approximately DKK 10 million - DKK 11 million in revenue.
공시 • May 03DanCann Pharma A/S to Report Q1, 2024 Results on May 31, 2024DanCann Pharma A/S announced that they will report Q1, 2024 results on May 31, 2024
공시 • May 01DanCann Pharma A/S, Annual General Meeting, May 30, 2024DanCann Pharma A/S, Annual General Meeting, May 30, 2024.
공시 • Apr 04Dancann Pharma A/S to Report Q3, 2024 Results on Apr 17, 2024Dancann Pharma A/S announced that they will report Q3, 2024 results on Apr 17, 2024